Okay, let's tackle this question. The question is about the difference between alteplase and streptokinase. First, I need to recall what these drugs are used for. Both are thrombolytics, right? They're used to break down blood clots. But how do they differ?

Alteplase is a recombinant tissue plasminogen activator (rtPA), while streptokinase is a bacterial protein. The key difference here is probably their mechanism of action. Alteplase directly activates plasminogen to form plasmin, which then lyses the clot. Streptokinase, on the other hand, forms a complex with plasminogen and converts it to plasmin, but it's non-specific. That might lead to more systemic fibrinolysis and higher risk of bleeding.

Wait, the options weren't provided, so I need to think of common distractors. Common questions about these drugs often compare their specificity, antigenicity, or side effects. For example, alteplase is specific to fibrin clots, whereas streptokinase isn't as specific. Also, streptokinase can cause allergic reactions because it's derived from bacteria. Another point is the half-life; alteplase has a longer half-life, so it's given as a bolus or infusion, while streptokinase might require continuous infusion.

So the correct answer would likely be that alteplase is fibrin-specific, leading to less systemic effects. The incorrect options might be about their source, method of administration, or something else. Let me structure the explanation accordingly. Make sure to mention the core concept about their mechanisms, why alteplase's specificity is better, and why the other options are wrong. Also, a clinical pearl about when to use each based on the patient's history of streptokinase use.

**Core Concept**
Alteplase and streptokinase are thrombolytic agents that activate plasminogen to plasmin, dissolving fibrin clots. **Alteplase (recombinant tPA)** is **fibrin-specific**, while **streptokinase** is **non-fibrin-specific** and forms a complex with plasminogen to indirectly activate plasmin. This specificity affects safety profiles and clinical use.

**Why the Correct Answer is Right**
Alteplase directly binds to fibrin in clots, enhancing localized plasmin generation and minimizing systemic fibrinolysis. This **fibrin specificity reduces bleeding risk** compared to streptokinase, which acts systemically. Alteplase’s mechanism avoids immune reactions (streptokinase is bacterial-derived), making it preferred in patients with prior streptokinase exposure or allergy.

**Why Each Wrong Option is Incorrect**
**Option A:** "Alteplase is derived from bacterial sources" – **Incorrect.** Alteplase is recombinant human tPA; streptokinase is derived from *Streptococcus*.
**Option B:** "Alteplase requires a longer infusion time" – **Incorrect.** Alteplase is often given as a bolus or short infusion, while streptokinase requires continuous infusion.
**Option C:** "Alteplase causes more frequent allergic reactions" – **Incorrect.**

✓ Correct Answer: D. Activates plasminogen bound to fibrin